Inhalable Biologics Market By Product Type (Monoclonal Antibodies, Peptides & Proteins, Nucleic Acid-Based Biologics, Vaccines, Others), By Application (Respiratory Diseases, Systemic Diseases, Infectious Diseases, Others), By Delivery Device (Dry Powder Inhalers, Metered-Dose Inhalers, Nebulizers, Soft Mist Inhalers, Smart Inhalers), By End-user (Hospitals & Clinics, Homecare Settings, Research & Academic Institutes, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Report Coverage:

By Product Type

• Monoclonal Antibodies
• Peptides & Proteins
• Nucleic Acid-Based Biologics
• Vaccines
• Others

By Application

• Respiratory Diseases
• Systemic Diseases
• Infectious Diseases
• Others

By Delivery Device

• Dry Powder Inhalers
• Metered-Dose Inhalers
• Nebulizers
• Soft Mist Inhalers
• Smart Inhalers

By End-user

• Hospitals & Clinics
• Homecare Settings
• Research & Academic Institutes
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• AstraZeneca
• GlaxoSmithKline
• Boehringer Ingelheim
• Novartis AG
• Sanofi
• MannKind Corporation
• Pulmatrix, Inc.
• Teva Pharmaceutical Industries Ltd.
• Insmed Incorporated
• Aerami Therapeutics
• Vectura Group
• 3M Health Care
• Chiesi Farmaceutici S.p.A
• Savara Inc.
• Aradigm Corporation